Cargando…

Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil

BACKGROUND: The coronavirus disease (COVID-19) pandemic has had enormous consequences in Brazil and worldwide. Patients with cancer affected by COVID-19 are at a higher risk of developing complications and worse outcomes compared to the non-cancer population, particularly the ones on active systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fares, Aline F, Fadul, Luiza A, Benetton, Barbara, Nogueira, Mauricio L, Lanza, Marcia, Araújo, Daniel V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426015/
https://www.ncbi.nlm.nih.gov/pubmed/34567254
http://dx.doi.org/10.3332/ecancer.2021.1269
_version_ 1783749957721784320
author Fares, Aline F
Fadul, Luiza A
Benetton, Barbara
Nogueira, Mauricio L
Lanza, Marcia
Araújo, Daniel V
author_facet Fares, Aline F
Fadul, Luiza A
Benetton, Barbara
Nogueira, Mauricio L
Lanza, Marcia
Araújo, Daniel V
author_sort Fares, Aline F
collection PubMed
description BACKGROUND: The coronavirus disease (COVID-19) pandemic has had enormous consequences in Brazil and worldwide. Patients with cancer affected by COVID-19 are at a higher risk of developing complications and worse outcomes compared to the non-cancer population, particularly the ones on active systemic treatment. Considering the COVID-19’s high transmissibility in asymptomatic and pre-symptomatic patients, we sought to determine the prevalence of COVID-19 infection in patients with solid cancers receiving systemic therapy in a Brazilian public health hospital. Furthermore, we studied whether socio-economic status was associated with prevalence. METHODS: Consecutive asymptomatic patients undergoing treatment for solid tumours at the chemotherapy and infusion centre of Hospital de Base were enrolled. Patients were prospectively tested for severe acute respiratory syndrome coronavirus 2 RNA real-time polymerase chain reaction with nasal and oropharyngeal swabs immediately prior to treatment. A socio-economic survey was carried out prior to testing. Demographic and socio-economic characteristics were summarised in means, medians and proportions. RESULTS: From 6 to 13 October 2020, 148 asymptomatic patients were identified. Of those, 41 were excluded, leaving 107 eligible patients. The mean age of the population was 58 years (SD ± 12.6); 54% were female and 90% were self-identified as White. The most common cancer sites were gastrointestinal tract (36%) and breast (25%). Most patients had a metastatic disease (59%) and were on anticancer treatment involving chemotherapy (95%). Regarding socio-economic status, 46% of our population had either primary school or illiterate as their highest educational level. In terms of monthly income, 92% had a personal income inferior to U$380 and 88% a household income inferior to U$585. Of the 107 patients tested, only 1 (0.9%) was positive for COVID-19. This is a 48-year-old man living in an urban area, with primary school educational level and a monthly personal income inferior to U$390. CONCLUSION: Despite a high prevalence of COVID-19 in Brazil, our cohort demonstrated a low prevalence of COVID-19 (0.9%) amongst asymptomatic patients with cancer. We hypothesise that patients with cancer, independent of their socio-economic status, are aware of the increased risk of developing a severe disease and are adherent to physical distancing, masking and hygiene measures.
format Online
Article
Text
id pubmed-8426015
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-84260152021-09-24 Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil Fares, Aline F Fadul, Luiza A Benetton, Barbara Nogueira, Mauricio L Lanza, Marcia Araújo, Daniel V Ecancermedicalscience Short Communication BACKGROUND: The coronavirus disease (COVID-19) pandemic has had enormous consequences in Brazil and worldwide. Patients with cancer affected by COVID-19 are at a higher risk of developing complications and worse outcomes compared to the non-cancer population, particularly the ones on active systemic treatment. Considering the COVID-19’s high transmissibility in asymptomatic and pre-symptomatic patients, we sought to determine the prevalence of COVID-19 infection in patients with solid cancers receiving systemic therapy in a Brazilian public health hospital. Furthermore, we studied whether socio-economic status was associated with prevalence. METHODS: Consecutive asymptomatic patients undergoing treatment for solid tumours at the chemotherapy and infusion centre of Hospital de Base were enrolled. Patients were prospectively tested for severe acute respiratory syndrome coronavirus 2 RNA real-time polymerase chain reaction with nasal and oropharyngeal swabs immediately prior to treatment. A socio-economic survey was carried out prior to testing. Demographic and socio-economic characteristics were summarised in means, medians and proportions. RESULTS: From 6 to 13 October 2020, 148 asymptomatic patients were identified. Of those, 41 were excluded, leaving 107 eligible patients. The mean age of the population was 58 years (SD ± 12.6); 54% were female and 90% were self-identified as White. The most common cancer sites were gastrointestinal tract (36%) and breast (25%). Most patients had a metastatic disease (59%) and were on anticancer treatment involving chemotherapy (95%). Regarding socio-economic status, 46% of our population had either primary school or illiterate as their highest educational level. In terms of monthly income, 92% had a personal income inferior to U$380 and 88% a household income inferior to U$585. Of the 107 patients tested, only 1 (0.9%) was positive for COVID-19. This is a 48-year-old man living in an urban area, with primary school educational level and a monthly personal income inferior to U$390. CONCLUSION: Despite a high prevalence of COVID-19 in Brazil, our cohort demonstrated a low prevalence of COVID-19 (0.9%) amongst asymptomatic patients with cancer. We hypothesise that patients with cancer, independent of their socio-economic status, are aware of the increased risk of developing a severe disease and are adherent to physical distancing, masking and hygiene measures. Cancer Intelligence 2021-07-26 /pmc/articles/PMC8426015/ /pubmed/34567254 http://dx.doi.org/10.3332/ecancer.2021.1269 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Fares, Aline F
Fadul, Luiza A
Benetton, Barbara
Nogueira, Mauricio L
Lanza, Marcia
Araújo, Daniel V
Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil
title Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil
title_full Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil
title_fullStr Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil
title_full_unstemmed Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil
title_short Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil
title_sort systematic sars-cov-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in brazil
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426015/
https://www.ncbi.nlm.nih.gov/pubmed/34567254
http://dx.doi.org/10.3332/ecancer.2021.1269
work_keys_str_mv AT faresalinef systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil
AT fadulluizaa systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil
AT benettonbarbara systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil
AT nogueiramauriciol systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil
AT lanzamarcia systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil
AT araujodanielv systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil